If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  FiF Test Found to Predict Prevalence of Cardiovascular Disease COPIAGUE, N.Y., May 8, 1996 -- American Biogenetic Sciences, Inc. (ABS) (Nasdaq: MABXA), announced today the results of a major epidemiological study using the Company's Functional Intact Fibrinogen (FiF(TM)) assay. A research group of the Framingham Heart Study reported that the FiF test is an accurate method for detecting elevated fibrinogen levels, one of the most recent and important risk factors in cardiovascular disease. The data were presented at the Third International Fibrinogen Symposium "Hemostasis, Inflammation and Cardiovascular Disease" held May 3-4, 1996 in Ulm, Germany. The FiF test has been evaluated for the past two years in an offspring population of the Framingham Epidemiology study. The findings demonstrate that the fibrinogen level measured by the FiF test was significantly correlated with the prevalence of cardiovascular disease both by itself and when adjusted for age, weight, smoking, and diabetes. In contrast, the fibrinogen levels as measured by the Clauss method, currently the predominant technique for measuring blood fibrinogen, was less significantly correlated with the prevalence of cardiovascular disease risk when adjusted for age, weight, smoking and diabetes in men. And in women, the association between fibrinogen and cardiovascular disease was not significant (after adjustment) when measured by the Clauss method. As the importance of fibrinogen in cardiovascular disease diagnosis is better recognized, and a reliable, convenient, fibrinogen assay becomes available for broad clinical use, the measurement of blood fibrinogen levels may be incorporated in the routine practice of preventive medicine, just as cholesterol testing has become routine. The Company believes that an accurate, simple test for the routine measurement of fibrinogen should have significant market potential. Commenting on the results of the study, Dr. Paul E. Gargan, President of [a href="http://www.pslgroup.com/dg/ABS.htm">ABS</a>], said, "The FiF test is a rapid, accurate and reproducible method for measuring fibrinogen levels in a patient's blood. The results from the Framingham Study suggest that the FiF test may become the optimal test, replacing the less accurate Clauss test for population screening." The patented FiF assay is fully quantitative, rapid, accurate, reproducible and adaptable to automated immunodiagnostic instruments. [a href="http://www.pslgroup.com/dg/ABS.htm">ABS</a>] anticipates filing a 510(k) for FiF during 1996. American Biogenetic Sciences, Inc. is a global biopharmaceutical and diagnostic company which conducts research and development in its laboratories located in South Bend, Indiana and through its Global Scientific Network(R) in the U.S., Europe, Israel and Russia. [a href="http://www.pslgroup.com/dg/ABS.htm">ABS</a>] seeks to discover and commercialize products in the fields of cardiology and neurobiology. The Company's enabling technology includes a patented Antigen-Free mouse colony which allows for the generation of highly specific monoclonal antibodies that cannot be acquired from conventional systems.
|
